---
document_datetime: 2023-09-21 17:28:43
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/daliresp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: daliresp-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.7373601
conversion_datetime: 2025-12-21 19:30:02.435468
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Daliresp

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                   | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|------------------------------------------------|----------------------------------|-----------|
| T/0030               | Application for Transfer of Marketing Authorisation from Takeda GmbH to AstraZeneca AB. Transfer of Marketing Authorisation                             | 14/10/2016                                  | 03/11/2016                                     | SmPC, Labelling and PL           |           |
| WS/1037              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Medicinal | 13/10/2016                                  | n/a                                            |                                  |           |

<!-- image -->

<!-- image -->

Medicinal product no longer authorised

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet).

The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    | - Introduction of, or change(s) to, the and conditions of a marketing including the RMP - Other variation                                                                                                                                                                                                                                                                                         |                    |                | C.I.11.z obligations authorisation,   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------|---------------------------------------|
| PSUSA/2658/ 201601 | Periodic Safety Update EU Single assessment - ROFLUMILAST                                                                                                                                                                                                                                                                                                                                         | 02/09/2016         | n/a            |                                       |
| IG/0699            | B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                                                                                                                                                            | 04/07/2016         | n/a authorised |                                       |
| IG/0691/G          | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of | 26/05/2016         | n/a no longer  | specification limits                  |
| WS/0924            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation Medicinal                                                                                             | 01/04/2016 product | n/a            |                                       |
| IG/0657            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV and/or changes in the                                                                                                                                                                                                                                                                             | 25/01/2016         | n/a            | (including contact details)           |

<div style=\"page-break-after: always\"></div>

|                    | PSMF location                                                                                                                                                                                                                                                                                                                                                                                                                      |                    |                      |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|----------------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| WS/0768            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4, 4.8, 5.1 and 5.2 5.1 of the SmPC in order to amend the safety information based on completion of Clinical Study RO-2455-404- RD (\"REACT\"). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/12/2015         | 03/11/2016           | SmPC                   | This procedure amend sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the safety information based on completion of Clinical Study RO-2455-404-RD (\"REACT\"). The REACT study was a randomized, double-blind, parallel- group, multicenter, placebo controlled phase 3b/4 study performed to investigate the efficacy and safety of roflumilast on top of a fixed dose of long-acting Beta 2- agonists (LABAs) and inhaled corticosteroids (ICS) in patients with severe COPD. Results indicate that treatment with roflumilast may lead to a higher risk of sleep disorders (mainly insomnia) in patients with a baseline body weight of <60 kg, due to a higher total PDE4 inhibitory activity found in these patients. authorised |
| T/0023             | Transfer of Marketing Authorisation from Takeda GmbH to Takeda GmbH.                                                                                                                                                                                                                                                                                                                                                               | 23/09/2015         | 28/10/2015 no longer |                        | Transfer of Marketing Authorisation from Takeda GmbH to Takeda GmbH.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| PSUSA/2658/ 201501 | Periodic Safety Update EU Single assessment - ROFLUMILAST                                                                                                                                                                                                                                                                                                                                                                          | 09/07/2015 product | n/a                  |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| R/0020             | Renewal of the marketing authorisation. Medicinal                                                                                                                                                                                                                                                                                                                                                                                  | 26/02/2015         | 24/04/2015           | SmPC, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considers that the benefit/risk profile of Daliresp continues to be favourable. The CHMP is of the opinion that an additional five-year renewal on the basis of pharmacovigilance grounds is required.                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| PSUSA/2658/ 201407   | Periodic Safety Update EU Single assessment - ROFLUMILAST                                                                                                                                                                                                                                                    | 22/01/2015         | 23/03/2015   | SmPC and PL                      | Please refer to roflumilast EMEA/H/C/PSUSA/2658/201407 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation                                                                                                                                                                                                                       |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0470              | B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the dossier) - Deletion of a supplier                                                                                                                                                                                  | 15/08/2014         | n/a          | authorised                       |                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUV/0016            | Periodic Safety Update                                                                                                                                                                                                                                                                                       | 10/07/2014         | n/a          |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                            |
| IG/0406              | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                              | 07/02/2014         | n/a          | longer                           |                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUV/0014            | Periodic Safety Update                                                                                                                                                                                                                                                                                       | 09/01/2014         | n/a no       |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                            |
| IG/0353              | C.I.12 - Inclusion or deletion of black symbol and explanatory statements for medicinal products in the list of medicinal products that are subject to additional monitoring                                                                                                                                 | 20/09/2013 product | 01/09/2014   | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                              |
| N/0012               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                             | 05/08/2013         | 01/09/2014   | PL                               | Update of the local representative's contact details for France and inclusion of an additional local representative of the MAH for the new Member State, Croatia.                                                                                                                                                                                                                            |
| WS/0352              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Addition of 'angioedema' as undesirable effect in section 4.8 of the SmPC with frequency 'rare' as requested by the CHMP following the assessment of Medicinal | 21/02/2013         | 26/03/2013   | SmPC, Annex II, Labelling and PL | A cumulative review of adverse drug reactions (ADR) reports of angioedema received in the framework of post- marketing surveillance since market introduction of roflumilast (05 July 2010 - 05 July 2012) revealed a total of 55 medically confirmed and non-medically confirmed cases reporting terms potentially suggestive of angioedema. Thirteen of these reports were serious, all of |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS A.5.a - Administrative change - Change in the name and/or address of a manufacturer responsible for batch release                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | authorised                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0245 | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure 13/12/2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| WS/0231 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of sections 4.4 and 4.8 of the Summary of Product Characteristics (SmPC) of roflumilast regarding the risk of psychiatric disorders in line with the available post-marketing data as requested by the CHMP following the assessment of the 2nd PSUR. Annex II and sections 2 and 4 of the Package Leaflet have been updated accordingly and the list of local representatives has been updated. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH 20/09/2012 Medicinal product | Annex PL In the reporting period of PSUR 2 for roflumilast (6 January 2011 - 5 July 2011), more than 26% of the ADRs reported were serious. Among these more than 26% reported an ADR related to a potentially risk of triggering suicide (suicidal ideation (17), attempt suicide (2), completed suicide (2)), and more than 40% reported an ADR related to depression (depression (16), depressed mode (2), anxiety (8), insomnia (4), nervousness (4)). During the reporting period, of the seventeen (17) cases of suicidal ideation, seven (7) occurred rapidly, already on the day of the start of treatment with roflumilast or within the first week of treatment. In eight (8) reports, time to onset, ranged between 10 days and 2.5 month and in two (2) reports the time to onset was unknown but reported rechallenge positive. Among these seventeen (17) cases, eight (8) reports presented a medical history of psychiatric problems related to depression, anxiety and panic disorders, alcohol problems and anorexia and six (6) reports no presented previous history of depression Despite the high prevalence and incidence of depression in |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           |                                                                                                                                                                                                                                                                                                                                                                                      |                       |               | patients with severe COPD, a causal relationship between roflumilast and suicidal ideation or behaviour can't be excluded. According to the post-marketing experience, suicidal ideation could appear in patients without a previous history of depression and the time to onset could range between one day and several weeks. In addition, medical history of psychiatric problems such as anxiety, panic disorders, anorexia and alcoholism, among others, could be risk factors of these ADR on suicidal ideation. authorised   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0215   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                       | 29/08/2012            | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0084   | A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS                                                                                                                                                                                                | 29/06/2011            | n/a longer    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0083/G | This was an application for a group of variations. C.I.9.c - Changes to an existing pharmacovigilance system as described in the DDPS - Change of the back-up procedure of the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of the pharmacovigilance system Medicinal | 29/06/2011 product no | n/a           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0001   | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                            | 23/05/2011            | n/a Labelling | SmPC, and PL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |